Outcome after cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy in patients with secondary pleural metastases

Background: The role of cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy (CRS+HITOC) for patients with secondary pleural metastases has scarcely been investigated. Patients and Methods: We conducted a retrospective, multicentre study investigating the outcome of CRS+HITOC...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hassan, Mohamed (VerfasserIn) , Zimmermann, Julia (VerfasserIn) , Schmid, Severin Thomas (VerfasserIn) , Passlick, Bernward (VerfasserIn) , Kovács, Julia Regina (VerfasserIn) , Hatz, Rudolf (VerfasserIn) , Winter, Hauke (VerfasserIn) , Klotz, Laura Valentina (VerfasserIn) , Eichhorn, Martin E. (VerfasserIn) , Markowiak, Till Marvin (VerfasserIn) , Müller, Karolina (VerfasserIn) , Huppertz, Gunnar (VerfasserIn) , Koller, Michael (VerfasserIn) , Hofmann, Hans-Stefan (VerfasserIn) , Ried, Michael (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 28 November 2023
In: Frontiers in oncology
Year: 2023, Jahrgang: 13, Pages: 1-9
ISSN:2234-943X
DOI:10.3389/fonc.2023.1259779
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fonc.2023.1259779
Verlag, lizenzpflichtig, Volltext: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1259779/full
Volltext
Verfasserangaben:Mohamed Hassan, Julia Zimmermann, Severin Schmid, Bernward Passlick, Julia Kovács, Rudolf Hatz, Hauke Winter, Laura V. Klotz, Martin E. Eichhorn, Till Markowiak, Karolina Müller, Gunnar Huppertz, Michael Koller, Hans-Stefan Hofmann and Michael Ried

MARC

LEADER 00000caa a2200000 c 4500
001 1889864374
003 DE-627
005 20250116101624.0
007 cr uuu---uuuuu
008 240527s2023 xx |||||o 00| ||eng c
024 7 |a 10.3389/fonc.2023.1259779  |2 doi 
035 |a (DE-627)1889864374 
035 |a (DE-599)KXP1889864374 
035 |a (OCoLC)1443679018 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Hassan, Mohamed  |e VerfasserIn  |0 (DE-588)1227415176  |0 (DE-627)1748456210  |4 aut 
245 1 0 |a Outcome after cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy in patients with secondary pleural metastases  |c Mohamed Hassan, Julia Zimmermann, Severin Schmid, Bernward Passlick, Julia Kovács, Rudolf Hatz, Hauke Winter, Laura V. Klotz, Martin E. Eichhorn, Till Markowiak, Karolina Müller, Gunnar Huppertz, Michael Koller, Hans-Stefan Hofmann and Michael Ried 
264 1 |c 28 November 2023 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 27.05.2024 
520 |a Background: The role of cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy (CRS+HITOC) for patients with secondary pleural metastases has scarcely been investigated. Patients and Methods: We conducted a retrospective, multicentre study investigating the outcome of CRS+HITOC for 31 patients with pleural metastases from different primary tumours in four high-volume departments of thoracic surgery in Germany. The primary endpoint was overall survival (OS). Secondary endpoints included postoperative complications and recurrence/progression-free survival (RFS/PFS). Results: The primary tumour was non-small cell lung cancer in 12 (39%), ovarian cancer in 5 (16%), sarcoma in 3 (10%), pseudomyxoma peritonei in 3 (10%), and others in 8 (26%) patients. A macroscopic complete resection (R/1) could be achieved in 28 (90%) patients. Major postoperative complications as classified by Clavien-Dindo (III-V) were observed in 11 (35%) patients. The postoperative mortality rate was 10% (n=3). A total of 13 patients received additive chemotherapy (42%). The median time of follow up was 30 months (95% CI = 17- 43). The median OS was 39 months (95% CI: 34-44 months) with 1-month, 3-month, 1-, 3-, and 5-year survival estimates of 97%, 89%, 77%, 66%, and 41%. There was a significantly prolonged OS in patients who received additive chemotherapy compared to patients with only CRS+HITOC (median OS 69 <italic>vs</italic> 38 months; p= 0.048). The median RFS was 14 months (95% CI: 7-21 months). Conclusions: We observed that CRS+HITOC is a feasible approach with reasonable complications and prolonged survival as a part of multimodal concept for highly selected patients with secondary pleural metastases. 
650 4 |a cytoreductive surgery2 
650 4 |a HITOC1 
650 4 |a hyperthermic intrathoracic chemotherapy5 
650 4 |a non-small cell lung cancer4 
650 4 |a pleural metastases3 
700 1 |a Zimmermann, Julia  |e VerfasserIn  |4 aut 
700 1 |a Schmid, Severin Thomas  |d 1986-  |e VerfasserIn  |0 (DE-588)1025974042  |0 (DE-627)725767634  |0 (DE-576)370971159  |4 aut 
700 1 |a Passlick, Bernward  |e VerfasserIn  |0 (DE-588)1112631305  |0 (DE-627)866700358  |0 (DE-576)476696348  |4 aut 
700 1 |a Kovács, Julia Regina  |d 1988-  |e VerfasserIn  |0 (DE-588)1313646105  |0 (DE-627)1876241802  |4 aut 
700 1 |a Hatz, Rudolf  |e VerfasserIn  |0 (DE-588)1271384515  |0 (DE-627)1820193020  |4 aut 
700 1 |a Winter, Hauke  |e VerfasserIn  |0 (DE-588)1162076038  |0 (DE-627)1025509773  |0 (DE-576)176791531  |4 aut 
700 1 |a Klotz, Laura Valentina  |d 1983-  |e VerfasserIn  |0 (DE-588)143075101  |0 (DE-627)641874685  |0 (DE-576)334894921  |4 aut 
700 1 |a Eichhorn, Martin E.  |d 1974-  |e VerfasserIn  |0 (DE-588)124436900  |0 (DE-627)363346627  |0 (DE-576)294170545  |4 aut 
700 1 |a Markowiak, Till Marvin  |d 1993-  |e VerfasserIn  |0 (DE-588)1209604884  |0 (DE-627)1697273920  |4 aut 
700 1 |a Müller, Karolina  |e VerfasserIn  |4 aut 
700 1 |a Huppertz, Gunnar  |e VerfasserIn  |4 aut 
700 1 |a Koller, Michael  |d 1992-  |e VerfasserIn  |0 (DE-588)1188440764  |0 (DE-627)1667392794  |4 aut 
700 1 |a Hofmann, Hans-Stefan  |d 1964-  |e VerfasserIn  |0 (DE-588)172638836  |0 (DE-627)697572811  |0 (DE-576)133497720  |4 aut 
700 1 |a Ried, Michael  |d 1982-  |e VerfasserIn  |0 (DE-588)140617914  |0 (DE-627)620232463  |0 (DE-576)319131424  |4 aut 
773 0 8 |i Enthalten in  |t Frontiers in oncology  |d Lausanne : Frontiers Media, 2011  |g 13(2023), Artikel-ID 1259779, Seite 1-9  |h Online-Ressource  |w (DE-627)684965518  |w (DE-600)2649216-7  |w (DE-576)35841184X  |x 2234-943X  |7 nnas  |a Outcome after cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy in patients with secondary pleural metastases 
773 1 8 |g volume:13  |g year:2023  |g elocationid:1259779  |g pages:1-9  |g extent:9  |a Outcome after cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy in patients with secondary pleural metastases 
856 4 0 |u https://doi.org/10.3389/fonc.2023.1259779  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1259779/full  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20240527 
993 |a Article 
994 |a 2023 
998 |g 124436900  |a Eichhorn, Martin E.  |m 124436900:Eichhorn, Martin E.  |d 910000  |d 950000  |d 950900  |e 910000PE124436900  |e 950000PE124436900  |e 950900PE124436900  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 9 
998 |g 143075101  |a Klotz, Laura Valentina  |m 143075101:Klotz, Laura Valentina  |d 910000  |d 950000  |d 950900  |e 910000PK143075101  |e 950000PK143075101  |e 950900PK143075101  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 8 
998 |g 1162076038  |a Winter, Hauke  |m 1162076038:Winter, Hauke  |d 910000  |d 950000  |d 950900  |d 50000  |e 910000PW1162076038  |e 950000PW1162076038  |e 950900PW1162076038  |e 50000PW1162076038  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |k 0/50000/  |p 7 
999 |a KXP-PPN1889864374  |e 4529910369 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1889864374","physDesc":[{"extent":"9 S."}],"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"28 November 2023"}],"relHost":[{"note":["Gesehen am 07.11.13"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"part":{"year":"2023","pages":"1-9","extent":"9","volume":"13","text":"13(2023), Artikel-ID 1259779, Seite 1-9"},"title":[{"title":"Frontiers in oncology","title_sort":"Frontiers in oncology"}],"id":{"zdb":["2649216-7"],"eki":["684965518"],"issn":["2234-943X"]},"pubHistory":["2011 -"],"origin":[{"dateIssuedDisp":"2011-","dateIssuedKey":"2011","publisherPlace":"Lausanne","publisher":"Frontiers Media"}],"disp":"Outcome after cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy in patients with secondary pleural metastasesFrontiers in oncology","physDesc":[{"extent":"Online-Ressource"}],"recId":"684965518"}],"person":[{"display":"Hassan, Mohamed","family":"Hassan","role":"aut","given":"Mohamed"},{"display":"Zimmermann, Julia","role":"aut","given":"Julia","family":"Zimmermann"},{"role":"aut","given":"Severin Thomas","family":"Schmid","display":"Schmid, Severin Thomas"},{"display":"Passlick, Bernward","given":"Bernward","role":"aut","family":"Passlick"},{"display":"Kovács, Julia Regina","role":"aut","given":"Julia Regina","family":"Kovács"},{"family":"Hatz","role":"aut","given":"Rudolf","display":"Hatz, Rudolf"},{"role":"aut","given":"Hauke","family":"Winter","display":"Winter, Hauke"},{"given":"Laura Valentina","role":"aut","family":"Klotz","display":"Klotz, Laura Valentina"},{"display":"Eichhorn, Martin E.","role":"aut","given":"Martin E.","family":"Eichhorn"},{"given":"Till Marvin","role":"aut","family":"Markowiak","display":"Markowiak, Till Marvin"},{"display":"Müller, Karolina","family":"Müller","role":"aut","given":"Karolina"},{"family":"Huppertz","given":"Gunnar","role":"aut","display":"Huppertz, Gunnar"},{"role":"aut","given":"Michael","family":"Koller","display":"Koller, Michael"},{"display":"Hofmann, Hans-Stefan","given":"Hans-Stefan","role":"aut","family":"Hofmann"},{"given":"Michael","role":"aut","family":"Ried","display":"Ried, Michael"}],"title":[{"title_sort":"Outcome after cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy in patients with secondary pleural metastases","title":"Outcome after cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy in patients with secondary pleural metastases"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 27.05.2024"],"name":{"displayForm":["Mohamed Hassan, Julia Zimmermann, Severin Schmid, Bernward Passlick, Julia Kovács, Rudolf Hatz, Hauke Winter, Laura V. Klotz, Martin E. Eichhorn, Till Markowiak, Karolina Müller, Gunnar Huppertz, Michael Koller, Hans-Stefan Hofmann and Michael Ried"]},"id":{"eki":["1889864374"],"doi":["10.3389/fonc.2023.1259779"]}} 
SRT |a HASSANMOHAOUTCOMEAFT2820